KY HB 532 Testimony & Talking Points (2021)

PCMA’s comment letter and talking points delivered to Kentucky leadership, in opposition to HB 532, which would allow government meddling in contract terms between private entities, and prohibit PBMs ability of utilizing preferred pharmacy networks.

IN SB 62 Testimony (2021)

PCMA submitted testimony against SB 62, which would require rebates negotiated by PBMs be applied to a patient’s cost sharing at the point of sale.

IN SB 131 Comment Letter (2021)

PCMA submits a comment letter opposing SB 131.  As introduced, the bill would require a health plan to provide a covered individual the wholesale acquisition cost (WAC) of a prescription drug that was dispensed or administered to that covered individual and require health plans to provide written notice to a covered individual of the amount […]

IL SB 2008 Talking Points (2021)

Talking points for IL SB 2008. As an omnibous PBM bill,  it would restrict preferred pharmacy networks by adding an AWP requirement and include a PBM fiduciary responsibility.

IL SB 2008 Testimony (2021)

PCMA submits testimony opposing SB 2008. As an  omnibous PBM bill, it would restrict preferred pharmacy networks by adding an AWP requirement and include a PBM fiduciary responsibility.

IL HB 711 Comment Letter (2021)

PCMA collaborates with others in the industry in a comment letter submitted by PCMA, ILHIC, IAMHP, and AHIP in opposition of HB 711, a bill aimed at limiting Prior Authorization and Step Therapy in Illinois.

IA HF 729 Cost Analysis (2021)

If enacted, IA HF 729 would cost the state $1.2 billion over next 10 years. HF 729 would instittue Any Willing Provider rules and restrict the use of preferred pharmacy networks, specialty pharmacies, and mail-order pharmacies.